VCU Massey Cancer Center receives $4.4 million NCI grant to support a statewide cancer clinical trials network, foster minority access to trials and focus research on cancer disparities
VCU Massey Cancer Center was awarded a $4.4 million, 5-year, renewable grant from the National Cancer Institute (NCI) to support a statewide network for cancer clinical research in Virginia that brings state-of-the-art clinical trials to patients in their own communities and emphasizes the inclusion of minorities in clinical trials and a focus on research that addresses cancer disparities. Massey is one of only 12 institutions in the nation to receive this type of grant that fosters access to cancer research for minority and medically underserved patients.
Massey researchers Steven Grant and Paul B. Fisher appointed to Cancer Research editorial board
VCU Massey Cancer Center researchers Steven Grant, M.D., and Paul B. Fisher, M.Ph., Ph.D., were recently recognized with an appointment by the most highly cited cancer journal in the world. Grant and Fisher were appointed to serve as members of the editorial board for Cancer Research, an American Association for Cancer Research (AACR) publication and the top scientific journal for articles of the broadest significance in the cancer research field.
Protein found to block benefits of vitamin A cancer therapy
Retinoic acid is a form of vitamin A that is used to treat and help prevent the recurrence of a variety of cancers, but for some patients the drug is not effective. The reason for this resistance was unclear until this week when researchers from Virginia Commonwealth University Massey Cancer Center demonstrated that a protein known as AEG-1 blocks the effects of retinoic acid in leukemia and liver cancer. Because AEG-1 is overexpressed in nearly every cancer, these findings could impact the care of countless cancer patients.
Scientists develop mouse model that could lead to new therapies for liver cancer
Researchers have created the first mouse model demonstrating the role of a cancer promoting gene, Astrocyte elevated gene-1 (AEG-1), in hepatocellular carcinoma, or liver cancer. The mouse model represents a critical step in understanding the molecular mechanisms of liver cancer progression and could lead to novel therapies for the disease.
Massey leader Harry Bear appointed to prestigious board
VCU Massey Cancer Center leader and physician-researcher Harry Bear, M.D., Ph.D., has been appointed to serve on the Board of Directors of the NSABP Foundation, Inc. The NSABP – National Surgical Adjuvant Breast and Bowel Project – Foundation is the world’s leading cooperative group for designing and conducting large-scale breast and colorectal cancer clinical trials. Supported by the National Cancer Institute (NCI) since its inception more than 50 years ago, the group has pioneered trials that have changed the way breast and bowel cancers are treated and prevented.